Cabergoline
As of the edition of 20 October 2026, Cabergoline is a small molecule: marketed, first approved in 1995 (CH); acts on DRD2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Dostinex
- First approved
- 28 June 1995 (CH)
- Approvals on record
- 9 in 7 regions
- Holder of the most recent approval
- Pfizer
- Registered trials
- 44, 2 stopped early
- Disease areas
- Hormones; Nervous system; Urinary and reproductive; Pregnancy and women's health; Cancer; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DRD2 | Dopamine receptor D2 | P14416 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 4 | 2 | 0 |
| Phase 1 | 5 | 4 | 1 | 0 |
| Phase 2 | 8 | 5 | 2 | 1 |
| Phase 3 | 13 | 6 | 3 | 0 |
| Phase 4 | 8 | 5 | 2 | 1 |
| All trials | 44 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Lead sponsor of trials | 1995 to now |